3SBio (OTCMKTS:TRSBF – Get Free Report) is expected to post its results after the market closes on Thursday, August 20th. Analysts expect 3SBio to post earnings of $0.0942 per share and revenue of $689.3230 million for the quarter.
3SBio Price Performance
TRSBF opened at $2.12 on Wednesday. The company has a fifty day moving average price of $2.16 and a two-hundred day moving average price of $2.52. 3SBio has a 1-year low of $2.00 and a 1-year high of $4.74.
3SBio Company Profile
3SBio Inc (OTCMKTS: TRSBF) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of protein-based therapeutics and chemical drugs. Established in 1999 and headquartered in Shenyang, Liaoning Province, the company has built an integrated platform that encompasses in-house R&D capabilities, clinical development, commercial production and a nationwide sales network.
The company’s product portfolio features a range of hematopoietic growth factors such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEPO), insulin and insulin analogs, hemostasis agents and monoclonal antibodies.
Further Reading
- Five stocks we like better than 3SBio
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for 3SBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 3SBio and related companies with MarketBeat.com's FREE daily email newsletter.
